Table 4.
Patients clinical and laboratorial data, according to ASST plus basophil test double-positivity or double-negativity.
| ASST and basophil test double-positive patients (n=24) | ASST and basophil test double-negative patients (n=36) | Chi-square | Odds ratio | Student test | |
|---|---|---|---|---|---|
| Male Gender | 3 (13%) | 7 (19%) | p=0.480 | 0.592 (0.137-2.560) | – |
| Presence of angioedema | 19 (79%) | 12 (33%) | p<0.05 | 7.600 (2.279-25.345) | – |
| Presence of nocturnal CSU symptoms | 17 (71%) | 16 (44%) | p<0.05 | 3.036 (1.012-9.107) | – |
| Symptoms for ≥5 days/week | 23 (96%) | 23 (64%) | p<0.05 | 13.000 (1.569-107.708) | – |
| Hives duration >5 hours | 16 (67%) | 13 (36%) | p<0.05 | 3.538 (1.193-10.499) | – |
| Presence of anti-TPO/Tg autoantibodies | 9 (38%) | 10 (28%) | p=0.471 | 1.500 (0.497-4.528) | – |
| Presence of fT4/TSH abnormalities | 5 (21%) | 3 (8%) | p=0.177 | 2.807 (0.602-13.091) | – |
| Presence of ANA/anti-dsDNA autoantibodies | 2 (8%) | 4 (11%) | p=0.780 | 0.775 (0.130-4.633) | – |
| IgE<30 U/mL | 12 (50%) | 4 (11%) | p<0.05 | 7.750 (2.084-28.815) | – |
| UAS7 (mean ± SD) | 22.3 ± 9.5 | 15.0 ± 10.3 | – | – | p<0.05 |
| DLQI (mean ± SD) | 9.7 ± 7.6 | 6.2 ± 5.6 | – | – | p<0.05 |
| UCT (mean ± SD) | 7.3 ± 4.2 | 9.8 ± 3.4 | – | – | p<0.05 |
| Total serum IgE (U/mL) | 85.6 ± 97.8 | 455.1 ± 1090.5 | – | – | p<0.05 |
| Ratio IgG-anti-TPO/Total IgE | 3.0 ± 6.7 | 0.3 ± 1.1 | – | – | p<0.05 |
ASST, autologous serum skin test; CSU, chronic spontaneous urticaria; anti-TPO, anti-thyroperoxidase; anti-Tg, anti-thyroglobulin; fT4, free thyroxine; TSH, thyroid stimulating hormone; ANA, antinuclear antibody; anti-dsDNA, anti-double stranded DNA; UAS7, urticaria activity score 7; DLQI, dermatological life quality index; UCT, urticaria control test.
Bold values highlight statistical significant values i.e. p < 0.05.